| 1. | | Recruiting | Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer
Conditions: Melanoma; Kidney Neoplasms; Metastases |
| 2. | | Recruiting | Treatment of Patients with Metastatic Renal Cell Cancer Using Cultured Tumor-Reactive Lymphocytes and Interleukin-2
Condition: Kidney Neoplasms |
| 3. | | Recruiting | Denileukin Diftitox to Treat Advanced Melanoma or Advanced Kidney Cancer
Conditions: Melanoma; Kidney Neoplasms |
| 4. | | Recruiting | Advanced Renal Cell Carcinoma
Conditions: Carcinoma, Renal Cell; Kidney Neoplasms |
| 5. | | Recruiting | Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
Conditions: Leiomyomatosis; Kidney Neoplasms |
| 6. | | Recruiting | CTLA-4 Antibody (MDX-010) to Treat Advanced Kidney Cancer
Condition: Kidney Neoplasm |
| 7. | | Recruiting | Electrocautery for Kidney Cancer
Condition: Kidney Neoplasm |
| 8. | | Recruiting | Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
Conditions: Breast Cancer; Colorectal Cancer; kidney tumor; Lung Cancer; Pancreatic Cancer; pleura cancer |
| 9. | | Recruiting | High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
Conditions: Breast Cancer; Gastrointestinal Cancer; Kidney Cancer; Musculoskeletal Cancer; Reproductive Cancer; Skin Cancer |
| 10. | | Recruiting | Genetic Polymorphisms in the RASSF1A Gene in Children With Wilms' Tumor
Conditions: recurrent Wilms' tumor and other childhood kidney tumors; stage I Wilms' tumor; stage II Wilms' tumor; stage III Wilms' tumor; stage IV Wilms' tumor; ... |
| 11. | | Recruiting | Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor
Conditions: Wilms' Tumor; Wilms' tumor and other childhood kidney tumors |
| 12. | | Recruiting | Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney
Conditions: recurrent Wilms' tumor and other childhood kidney tumors; clear cell sarcoma of the kidney |
| 13. | | Recruiting | 17AAG to Treat Kidney Tumors in von Hippel-Lindau Disease
Conditions: Hippel-Lindau Disease; Kidney Cancer |
| 14. | | Recruiting | Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell |
| 15. | | Recruiting | Cellular Adoptive Immunotherapy and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
Conditions: Stage IV Renal Cell Cancer; recurrent renal cell cancer |
| 16. | | Recruiting | Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer |
| 17. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer; renal clear cell carcinoma |
| 18. | | Recruiting | Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer
Conditions: stage III renal cell cancer; Stage IV Renal Cell Cancer; renal clear cell carcinoma |
| 19. | | Recruiting | Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Kidney Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer; renal clear cell carcinoma |
| 20. | | Recruiting | PEG-Interferon alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
Condition: Stage IV Renal Cell Cancer |
| 21. | | Not yet recruiting | SU011248 in the Treatment of Patients with Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma
Condition: Renal Cell Carcinoma |
| 22. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Von Hippel-Lindau Disease and Kidney Cancer
Conditions: stage I renal cell cancer; von Hippel-Lindau Syndrome |
| 23. | | Recruiting | Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer
Conditions: recurrent renal cell cancer; stage III renal cell cancer; Stage IV Renal Cell Cancer |
| 24. | | Recruiting | RNA-Loaded Dendritic Cell Cancer Vaccine
Condition: Renal Cell Carcinoma |
| 25. | | Recruiting | FR901228 in Treating Patients With Advanced Cancer of the Urothelium
Conditions: Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer |
| 26. | | Recruiting | Monoclonal Antibody Therapy in Treating Patients With Kidney Cancer
Conditions: renal clear cell carcinoma; stage I renal cell cancer; stage II renal cell cancer; stage III renal cell cancer; Stage IV Renal Cell Cancer |
| 27. | | Recruiting | Vaccine Therapy Combined With Interleukin-2 and Interferon alfa in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer)
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer |
| 28. | | Recruiting | Capecitabine Plus GTI-2040 in Treating Patients With Advanced or Metastatic Renal Cell Cancer
Conditions: Stage IV Renal Cell Cancer; recurrent renal cell cancer |
| 29. | | Recruiting | A Phase II Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
Condition: Stage IV Renal Cell Cancer |
| 30. | | Recruiting | SU011248 versus Interferon-alfa as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma
Condition: Renal Cell Carcinoma |
| 31. | | Recruiting | Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer |
| 32. | | Recruiting | SU011248 in Treating Patients With Cytokine-Refractory Metastatic Renal Cell Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer; renal clear cell carcinoma |
| 33. | | Recruiting | Short-Term Low-Dose Interferon alfa in Treating Patients With Cancer of the Urothelium
Conditions: Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer |
| 34. | | Recruiting | Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients with Metastatic Renal Cell Carcinoma
Condition: Renal Cell Carcinoma |
| 35. | | Recruiting | Avastin With or Without Erlotinib for Treatment of Metastatic Renal Cell Carcinoma
Condition: Renal Cell Cancer |
| 36. | | Recruiting | Continued Use of Monoclonal Antibody ABX-EGF in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer)
Condition: Stage IV Renal Cell Cancer |
| 37. | | Recruiting | High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer |
| 38. | | Recruiting | Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
Conditions: stage III bladder cancer; regional transitional cell cancer of the renal pelvis and ureter; anterior urethral cancer; posterior urethral cancer; ... |
| 39. | | Recruiting | AG-013736 as Second-Line Therapy in Treating Patients With Metastatic Renal Cell (Kidney) Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer |
| 40. | | Not yet recruiting | Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer
Conditions: stage III renal cell cancer; Stage IV Renal Cell Cancer; recurrent renal cell cancer |
| 41. | | Recruiting | Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have von Hippel-Lindau Syndrome or Are at Risk for von Hippel-Lindau Syndrome
Conditions: Renal Cell Cancer; von Hippel-Lindau Syndrome |
| 42. | | Recruiting | Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
Conditions: Stage IV Renal Cell Cancer; recurrent renal cell cancer |
| 43. | | Recruiting | Study of BAY 43-9006 in Patients with Unresectable and/or Metastatic Renal Cell Cancer
Condition: Carcinoma, Renal Cell |
| 44. | | Recruiting | Bortezomib in Treating Patients With Advanced Transitional Cell Carcinoma of the Urothelium
Conditions: Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer |
| 45. | | Recruiting | Interferon alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
Conditions: stage III renal cell cancer; Stage IV Renal Cell Cancer; renal clear cell carcinoma; recurrent renal cell cancer |
| 46. | | Recruiting | Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma (Kidney Cancer)
Conditions: stage III renal cell cancer; Stage IV Renal Cell Cancer; recurrent renal cell cancer |
| 47. | | Recruiting | Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy
Conditions: Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer |
| 48. | | Recruiting | Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
Conditions: recurrent bladder cancer; stage IV bladder cancer; metastatic transitional cell cancer of the renal pelvis and ureter; ... |
| 49. | | Recruiting | FR901228 in Treating Patients With Metastatic Renal Cell Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer |
| 50. | | Recruiting | Oblimersen and Interferon alfa in Treating Patients With Metastatic Renal Cell Cancer
Conditions: Stage IV Renal Cell Cancer; recurrent renal cell cancer |
